Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: Menopause. 2020 Jan;27(1):57–65. doi: 10.1097/GME.0000000000001418

Figure 2.

Figure 2.

Initial hot flash frequency predicts therapeutic outcomes of PhytoSERM on hot flash frequency reduction in the PS50 group only. 2A, no correlation was observed in the placebo group; 2B and 2C, participants with higher initial hot flash frequency showed greater reduction in hot flash frequency in PS50 and PS100 respectively. PS50, PhytoSERM 50gm/day; PS100, PhytoSERM 100mg/day.